The opportunity in psychedelics for approved therapies could be much more expansive than it has been in cannabis…

EntheoTech holds over 200 exclusive psilocybin-containing mushroom strains and procedures in the extraction and implementation of these medicines, paving the way for EntheoTech to be one of the first companies in North America to provide a clinical trial-backed protocol and formula for natural macro and microdosing.

Download Investor Deck

Fill out the form below to download our investor deck.

Name(Required)
This field is for validation purposes and should be left unchanged.

1 in 5 Canadians experience a mental illness or addiction problems

Conditions such as depression and anxiety affect such an incredible number of people in our modern world, and are not treated well by pharmaceuticals. We believe in the potential of psilocybin, and EntheoTech is on a pathway to commercializing and delivering approved therapies to the market at scale.

Mental Health in 2022
1m+

of adults in North America have reported symptoms of depression

1.0m

people in the US are affected by post-traumatic stress disorder

1%

of people who need treatment, actually receive it

The Future of Mental Health

Mental health issues such as depression and anxiety afflict one in four people, and the global economic impact is over $2.5 trillion annually.

Traditional treatments can be ineffective for some patients. We focus on Psychedelic Assisted Therapies in conjunction with innovative treatment programs for long lasting change.

Have A Question Before Booking?

We’re here to help. Sign up to receive all the latest info about psychedelic-assisted therapy for mental health, chronic pain and for direct support from our medical team.

Scientifically researched & developed solutions with 100+ years experience

Menu